/ /

  • linkedin
  • Increase Font
  • Sharebar

    5 questions your patients need answered about the solar eclipse

    Darryl Glover, OD, and Jennifer Lyerly, ODOn August 21, the skies over a 70-mile wide path from Oregon to South Carolina will darken as the sun is completely blocked by the moon in a rare total solar eclipse.

    Americans haven’t had a chance to see such a cosmic event since 1979, and 500 million people across North America will experience at least a partial eclipse in action.

    With such an historic occasion, viewing the eclipse is generating plenty of buzz and doing so safely is of utmost importance. 

    Previously from Defocus Media: The next frontier: Mobile eyecare clinics

    As optometrists, we are the point persons for our community’s concerns and questions about eye health and vision, and many of us will be fielding questions about how to view the eclipse safely as the day draws near.

    Our podcast with Omar Punjabi, MD, retinal specialist at Charlotte Eye, Ear, Nose, and Throat, discusses the science behind solar retinopathy and how eclipse glasses give protection that standard eyewear can’t. He answers the top questions your patients will ask, and gives advice on how to best utilize the event for practice marketing.

    Listen to more audio content from Defocus Media and Optometry Times here

    Darryl Glover, OD
    Dr. Glover is a global optometrist, entrepreneur, and social media expert. He received his Doctorate of Optometry from Salus University. ...
    Jennifer Lyerly, OD
    Dr. Lyerly is a 2011 graduate of Southern College of Optometry. She founded Eyedolatry in 2011, a media platform dedicated to ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V